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Age  53 ± 8.2  58 ± 7.7  <0.001  53 ± 8.1  54 ± 8.6  0.1 
Gender (%)       0.9       0.03 
  Male  250 (42.7)  110 (42.6)    187 (40.4)  63 (51.2)   
  Female  336 (57.3)  148 (57.4)    276 (59.6)  60 (48.8)   
Ethnicity (%)      <0.001      0.05 
  White  250 (42.7)  88 (34.1)    200 (43.2)  50 (40.7)   
  African American  139 (23.7)  95 (36.8)    100 (21.6)  39 (31.7)   
  Non‐white Hispanic  197 (33.6)  75 (29.1)    163 (35.2)  34 (27.6)   
IGT Status (%)       < 0.0001       0.1 
  Normal  424 (72.4)  146 (56.6)    342 (73.9)  82 (66.7)   
  IGT  162 (27.7)  112 (43.4)    121 (26.1)  41 (33.3)   
Smoking Status (%)      0.1       0.08 
  Never  273 (46.6)  121 (46.9)    223 (48.2)  50 (40.7)   
  Past  221 (37.7)  110 (42.6)    164 (35.4)  57 (46.3)   
  Current  92 (15.7)  27 (10.5)    76 (16.4)  16 (13)   
             
BMI  27.6 ± 5.2  30.2 ± 6.1   0.0001  27.37 ± 5.07  28.58 ± 5.73  0.03 
F2‐isoP1  0.25 ± 0.18  0.24 ± 0.2  0.04  0.25 ± 0.18  0.24 ± 0.23  0.1 
F2‐isoP2  4.29 ± 3.07  4.47 ± 2.84  0.4  4.39 ± 3.21  3.86 ± 2.46  0.02 
F2‐isoP3  6.7 ± 4.14  6.01 ± 4.2  0.001  6.76 ± 4.06  6.48 ± 4.44  0.1 
F2‐isoP4  4.17 ± 2.76  4.08 ± 3.11  0.2  4.19 ± 2.78  4.07 ± 2.66  0.6 













































0.19 (0.16)  3.19 (1.85)  5.01 (3.12)  3.77 (2.44)  ‐0.29 (0.62) 
  Female  













0.19 (0.15)  3.59 (2.06)  5.08 (2.98)  3.26 (2.03)  ‐0.31 (0.56) 
  Hispanic 
 
0.31 (0.24)  5.31 (4.04)  8.02 (4.99)  4.93 (3.47)  0.32 (1.02) 
  p‐value a 
 
P<0.0001  P<0.0001  P<0.0001  P<0.0001  P<0.0001 
IGT Status  Normal 
 
0.25 (0.21)  4.19 (3.01)  6.42 (3.99)  4.09 (2.91)  ‐0.02 (0.83) 
  IGT 
 
0.24 (0.16)  4.64 (2.96)  6.65 (4.52)  4.24 (2.78)  0.03 (0.79) 
  p‐value a 
 





0.24 (0.18)  4.34 (2.69)  6.75 (4.36)  4.2 (2.83)  0.01 (0.79) 
  Past 
 
0.23 (0.16)  4.17 (3.27)  6.08 (4.05)  3.94 (2.64)  ‐0.09 (0.79) 
  Current  




P<0.0001  P=0.05  p=0.02  P=0.15  P<0.001 
Continuous anthropometric baseline characteristics.  Spearman correlation coefficients (p‐value) 
Age     ‐0.01 (0.7)  ‐0.03 (0.3)  ‐0.03 (0.4)  ‐0.19 (<0.001)  ‐0.07 (0.04) 
BMI     0.0 (0.9)  0.18 (<0.001)  0.04 (0.3)  0.1 (0.004)  0.09(0.007) a Wilcoxon rank sum/ Kruskal‐ Wallis  test 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5.3 Adjusted Associations Hypertension Status and F2‐Isoprostanes 
  The minimally and fully adjusted odds of prevalent hypertension (Table 3) were 
calculated using two sets of covariates as defined in the Methods section.  Overall, there 
was no consistent association between F2‐isoP and hypertension prevalence, as the OR 
point estimates ranged from 0.81 to 1.05 in the reduced model and 0.82 to 1.05 in the 
full model.  However, a marginal inverse association was found between F2‐IsoP3 and 
hypertension prevalence in the reduced (C.I. 95%=0.67,0.99) and the full model (C.I. 
95%= 0.68,0.99).  
Table 3.  Multivariable logistic regression of baseline hypertension on F2‐isoprostanes 
 
Baseline Hypertension (n=258) 
 
F2‐isoprostanes 
(ng/mg creatinine)  OR
a  (95%CI)  ORa (95% CI) 
 
Model 1b  Model 2c 
F2‐IsoP1 [iPF(2𝛼)‐III] 
 
0.99 (0.83,1.19)  1.02 (0.85,1.23) 
F2‐IsoP2 [2,3‐dinor‐iPF(2𝛼)‐III] 
 
0.98 (0.83,1.16)  0.99 (0.83,1.17) 
F2‐IsoP3 [iPF(2𝛼)‐IV] 
 
0.81 (0.67,0.99)  0.82 (0.68,0.99) 
F2‐IsoP4 [8,12‐iso‐iPF(2𝛼)‐IV] 
 
1.05 (0.88,1.24)  1.05 (0.88,1.25) 
F2‐isoP Index  0.94 (0.78,1.14)  0.96 (0.79,1.15) 
Factor 1  0.95 (0.79, 1.16)  0.92 (0.77, 1.10) 
Factor 2  1.01 (0.86, 1.18)  0.99 (0.84, 1.16) 
CI, confidence interval; OR, odds ratio 
a Odds ratios scaled by respective standard deviation 
b Reduced model adjusted for the following variables: age, gender,  race/ethnicity, clinic, BMI 
c Full model adjusted for the following variables: age, gender, race/ethnicity, clinic, smoking status, IGT 
status, BMI 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 In a similar manner, the associations between F2‐isoP and incident hypertension 
were examined (Table 4).  In both the fully and minimally adjusted models, none of F2‐
isoPs predicted a significant change in the odds of incident hypertension.  These results 
do not support the theory that increased oxidative status is causally related to 
hypertension.   
Table 4.  Multivariable logistic regression of incident hypertension on F2‐isoprostanes 
  Hypertension at follow‐up (n=463) 
F2‐isoprostanes 
(ng/mg creatinine)  OR
a (95%CI)  ORa (95% CI) 
 
Model 1b  Model 2c 
F2‐IsoP1 [iPF(2𝛼)‐III] 
 
1.06 (0.85, 1.31)  1.08 (0.86,1.36) 
F2‐IsoP2 [2,3‐dinor‐iPF(2𝛼)‐III] 
 
0.84 (0.62, 1.13)  0.84 (0.62, 1.13) 
F2‐IsoP3 [iPF(2𝛼)‐IV] 
 
1.01 (0.80, 1.27)  1.0 (0.79,1.27) 
F2‐IsoP4 [8,12‐iso‐iPF(2𝛼)‐IV] 
 
1.04 (0.84, 1.29)  1.05 (0.85,1.31) 
F2‐isoP Index 
 
0.99 (0.78, 1.26)  1.0 (0.8, 1.3) 
Factor 1 
 
0.96 (0.74, 1.25)  0.88 (0.69, 1.12) 
Factor 2 
 
0.81 (0.63, 1.06)  0.77 (0.60, 1.01) 
CI, confidence interval; OR, odds ratio 
a Odds ratios scaled by respective standard deviation 
b Reduced model adjusted for the following variables: age, gender, race/ethnicity, clinic, BMI 
c Full model adjusted for the following variables: age, gender, race/ethnicity, clinic, smoking status, IGT 
status, BMI 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Chapter 6 
Discussion 
6.1 Primary Findings 
  Using the cross‐sectional and prospective designs, this analysis investigated the 
association between urinary F2‐isoP and hypertension status in a large cohort with 
demographic, anthropometric, and metabolic diversity.  This study produced two main 
findings.  First, the analysis could not establish a significant relationship between 
increased oxidative status and hypertension prevalence.  After controlling for a minimal 
set of potential confounders, the ORs associated with seven F2‐isoP measurements 
ranged from 0.81 to 1.05.  Similarly, the range of the fully adjusted ORs ranged from 
0.82 to 1.05.  These findings are consistent and in agreement with previously published 
studies that found no evidence of increased F2‐IsoP levels among the prevalent 
hypertensive cases (52, 53).   
  With respect to incident hypertension, to the best of our knowledge, this is the 
first study to conduct a prospective study between F2‐isoP levels and hypertension.  The 
minimally and fully adjusted odds ratios ranged from 0.81 to 1.06 and from 0.77 to 1.08, 
respectively, with none of the associations reaching statistical significance.  These 
results suggest that increased oxidative status, as measured by F2‐isoP, is not causally 
related to hypertension pathogenesis.  Other lines of evidence support this reasoning.  
First, it has been shown that ROS generation occurs because of endothelial dysfunction 
(55).  One study also showed that men treated with anti‐hypertensive medication 
exhibited lower concentrations of F2‐isoP compared to untreated controls (53). 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Additionally, large clinical trials of antioxidants have shown inconsistent results in 
reducing blood pressure (56).    
  Interestingly, two sets of crude associations also contradict the original 
hypothesis that increased oxidative status is casually associated with hypertension. 
African‐Americans exhibited the lowest baseline concentrations of F2‐isoP, yet also 
exhibited the greatest proportion of hypertensive cases at baseline and follow‐up.  If the 
original hypothesis were true, we would expect to see a direct association between the 
primary exposure and outcome.   
6.2 Secondary Findings 
  Importantly, several expected associations between known risk factors and 
hypertension have been found.  For example, this study found that age differed 
significantly between baseline normotensives and their hypertensive counterparts. 
Accordingly, age is a known risk factor for hypertension and cardiovascular disease (12).  
Interestingly, this association was not present in the crude prospective association.  One 
reason for this may be a lack of age variability in the sub‐group who were normotensive 
at baseline.  While previous studies found a positive association between F2‐isoP and 
age (5), this analysis found significant inverse associations between age and two of the 
four F2‐isoP measurements.  One possible explanation for this association is that 
oxidative metabolism capacity declines with age.  Additionally, this study found 
expected crude associations between hypertension status and race/ethnicity (57), IGT 
status (18), and BMI (58).  Although positive associations between hypertension and F2‐
isoP concentrations have been found in previous cross‐sectional studies (46, 47, 49, 59), 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the cross‐sectional associations were marginally significant in this study, suggesting a 
potential protective trait of increased oxidative status.  Indeed, some researchers 
theorize that an increased concentration of F2‐isoPs reflect a favorable trait and infers a 
reduced risk of weight gain and development of diabetes (60).    
  The unadjusted associations between baseline study characteristics and F2‐isoP 
species produced several expected findings.  F2‐isoP levels differed significantly between 
males and females.  However, this may be explained by the adjustments made for 
urinary diluteness during quantification of urinary biomarkers.  Specifically, corrections 
for creatinine levels were made to all F2‐isoP concentrations.  Since creatinine levels are 
influenced by the lean muscle mass, these adjustments can increase observed 
concentrations among women, because women on average have lower muscle as 
compared to men (60).  This study also reproduced associations between F2‐isoP and 
smoking status (41) and BMI (58).    
6.3 Conclusion 
  Despite advances in prevention and treatment, hypertension is still one of the 
most common conditions in the world, and for a majority of cases the causal 
mechanisms remain to be fully understood.  Many experimental studies have implicated 
oxidative stress in the pathogenesis of hypertension.  However, epidemiological studies 
have not provided consistent results.  Additionally, most of the epidemiological studies 
are cross sectional and thus, cannot establish temporal relationships between the 
exposure and outcome.  The main objective of this study was to investigate the 
prospective relationship between oxidative status, as measured by F2‐isoP, and 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hypertension incidence.  The results of this study do not support the hypothesis that 
elevated oxidative status can inform hypertension risk.  While this study implemented 
the prospective design to establish a temporal relationship between oxidative stress 
status and hypertension there were several inherent limitations.  These include 
dichotomization of hypertension and a lack of repeated blood pressure and F2‐isoP 
observations during the five‐year study period.  Additionally, oxidative status must be 
assessed indirectly through oxidative damage.  Since there are multiple biological 
pathways involved with hypertension, additional measures of oxidative damage may 
provide a more comprehensive assessment of oxidative stress status. 
 
 
 
 
 
 
       
  23 
Bibliography  
1.  Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics‐‐2014 
update: a report from the American Heart Association. Circulation 
2014;129(3):e28‐e292. 
2.  Quam L, Smith R, Yach D. Rising to the global challenge of the chronic disease 
epidemic. Lancet 2006;368(9543):1221‐3. 
3.  Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. 
Circulation 2000;101(3):329‐35. 
4.  Beevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of 
hypertension. BMJ (Clinical Research Ed) 2001;322(7291):912‐6. 
5.  El Assar M, Angulo J, Rodríguez‐Mañas L. Oxidative stress and vascular 
inflammation in aging. Free Radical Biology & Medicine 2013;65:380‐401. 
6.  Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of 
Internal Medicine 2003;139(9):761‐76. 
7.  Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560‐72. 
8.  Moore J. Hypertension: catching the silent killer. The Nurse Practitioner 
2005;30(10):16. 
9.  Lemogoum D. Challenge for hypertension prevention and control worldwide: the 
time for action. Journal Of Clinical Hypertension (Greenwich, Conn) 
2014;16(8):554‐6. 
10.  Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling 
hypertension: impact of hypertensive subtype, stage, age, and sex. American 
Heart Journal 2003;145(5):888‐95. 
11.  Robbins SL, Vinay Kumar, and Ramzi S. Cotran. Robbins and Cotran pathologic 
basis of disease. Philadelphia, PA: Saunders/Elsevier; 2010  
12.  Bolívar JJ. Essential Hypertension: An Approach to Its Etiology and Neurogenic 
Pathophysiology. International Journal of Hypertension 2013:1‐11. 
13.  Harrison DG. The mosaic theory revisited: common molecular mechanisms 
coordinating diverse organ and cellular events in hypertension. Journal Of The 
American Society Of Hypertension: JASH 2013;7(1):68‐74. 
14.  Montecucco F, Pende A, Quercioli A, et al. Inflammation in the pathophysiology 
of essential hypertension. Journal Of Nephrology 2011;24(1):23‐34. 
15.  Klatsky AL, Gunderson E. Alcohol and hypertension: a review. Journal of the 
American Society of Hypertension : JASH 2008;2(5):307‐17. 
16.  Sodium, potassium, body mass, alcohol and blood pressure: the INTERSALT 
Study. The INTERSALT Co‐operative Research Group. Journal Of Hypertension 
Supplement: Official Journal Of The International Society Of Hypertension 
1988;6(4):S584‐S6. 
  24 
17.  Hall WD, Ferrario CM, Moore MA, et al. Hypertension‐related morbidity and 
mortality in the southeastern United States. Am J Med Sci 1997;313(4):195‐209. 
18.  Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic 
abnormalities‐‐the role of insulin resistance and the sympathoadrenal system. 
The New England Journal Of Medicine 1996;334(6):374‐81. 
19.  Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular 
perspective. Annual Review Of Medicine 2005;56:45‐62. 
20.  Hypertension primer the essentials of high blood pressure: basic science, 
population science and clinical management. Philadelphia, PA: Lippincott 
Williams & Wilkins; 2008. 
21.  Harrison DG. The mosaic theory revisited: common molecular mechanisms 
coordinating diverse organ and cellular events in hypertension. Journal of the 
American Society of Hypertension : JASH 2013;7(1):68‐74. 
22.  Manrique C, Lastra G, Gardner M, et al. The renin angiotensin aldosterone 
system in hypertension: roles of insulin resistance and oxidative stress. The 
Medical clinics of North America 2009;93(3):569‐82. 
23.  McGill JB, Haffner S, Rees TJ, et al. Progress and controversies: treating obesity 
and insulin resistance in the context of hypertension. Journal Of Clinical 
Hypertension (Greenwich, Conn) 2009;11(1):36‐41. 
24.  Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying 
insulin resistance, diabetes, and cardiovascular disease? The common soil 
hypothesis revisited. Arteriosclerosis, Thrombosis, And Vascular Biology 
2004;24(5):816‐23. 
25.  Dröge W. Free radicals in the physiological control of cell function. Physiological 
Reviews 2002;82(1):47‐95. 
26.  Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal 
physiological functions and human disease. The International Journal Of 
Biochemistry & Cell Biology 2007;39(1):44‐84. 
27.  Montezano AC, Touyz RM. Molecular mechanisms of hypertension‐‐reactive 
oxygen species and antioxidants: a basic science update for the clinician. The 
Canadian Journal Of Cardiology 2012;28(3):288‐95. 
28.  Montezano AC, Touyz RM. Oxidative stress, Noxs, and hypertension: 
experimental evidence and clinical controversies. Annals Of Medicine 2012;44 
Suppl 1:S2‐S16. 
29.  Martin C, Cameron J, McGrath B. Mechanical and circulating biomarkers in 
isolated clinic hypertension. Clinical And Experimental Pharmacology & 
Physiology 2008;35(4):402‐8. 
30.  González J, Valls N, Brito R, et al. Essential hypertension and oxidative stress: 
New insights. World Journal Of Cardiology 2014;6(6):353‐66. 
31.  Portaluppi F, Boari B, Manfredini R. Oxidative stress in essential hypertension. 
Current Pharmaceutical Design 2004;10(14):1695‐8. 
32.  Harrison DG, Gongora MC, Guzik TJ, et al. Oxidative stress and hypertension. 
Journal Of The American Society Of Hypertension: JASH 2007;1(1):30‐44. 
  25 
33.  Zalba G, San José G, Moreno MU, et al. Oxidative stress in arterial hypertension: 
role of NAD(P)H oxidase. Hypertension 2001;38(6):1395‐9. 
34.  Minuz P, Patrignani P, Gaino S, et al. Determinants of platelet activation in 
human essential hypertension. Hypertension 2004;43(1):64‐70. 
35.  Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin‐induced 
hypertension. American Journal Of Physiology Regulatory, Integrative And 
Comparative Physiology 2003;284(4):R893‐R912. 
36.  Sowers JR. Hypertension, angiotensin II, and oxidative stress. The New England 
Journal Of Medicine 2002;346(25):1999‐2001. 
37.  Bauer J, Ripperger A, Frantz S, et al. Pathophysiology of isoprostanes in the 
cardiovascular system: implications of isoprostane‐mediated thromboxane A2 
receptor activation. British Journal Of Pharmacology 2014;171(13):3115‐31. 
38.  Il'yasova D, Scarbrough P, Spasojevic I. Urinary biomarkers of oxidative status. 
CLINICA CHIMICA ACTA 2012;413(19‐20):1446‐53. 
39.  Basu S. Fatty acid oxidation and isoprostanes: oxidative strain and oxidative 
stress. Prostaglandins, Leukotrienes, And Essential Fatty Acids 2010;82(4‐6):219‐
25. 
40.  Basu S. Bioactive eicosanoids: Role of prostaglandin F and F‐isoprostanes in 
inflammation and oxidative stress related pathology. Molecules & Cells 
2010;30(5):383‐91. 
41.  Basu S, Helmersson J, Jarosinska D, et al. Regulatory factors of basal F(2)‐
isoprostane formation: population, age, gender and smoking habits in humans. 
Free Radical Research 2009;43(1):85‐91. 
42.  Morrow JD. The isoprostanes ‐ unique products of arachidonate peroxidation: 
their role as mediators of oxidant stress. Current Pharmaceutical Design 
2006;12(8):895‐902. 
43.  Richelle M, Turini ME, Guidoux R, et al. Urinary isoprostane excretion is not 
confounded by the lipid content of the diet. FEBS Letters 1999;459(2):259‐62. 
44.  Basu S. F2‐isoprostanes in human health and diseases: from molecular 
mechanisms to clinical implications. Antioxidants & Redox Signaling 
2008;10(8):1405‐34. 
45.  Cracowski J‐L, Ormezzano O. Isoprostanes, emerging biomarkers and potential 
mediators in cardiovascular diseases. European Heart Journal 2004;25(19):1675‐
8. 
46.  Dołegowska B, Błogowski W, Kedzierska K, et al. Platelets arachidonic acid 
metabolism in patients with essential hypertension. Platelets 2009;20(4):242‐9. 
47.  Cottone S, Mulè G, Nardi E, et al. Relation of C‐reactive protein to oxidative 
stress and to endothelial activation in essential hypertension. American Journal 
Of Hypertension 2006;19(3):313‐8. 
48.  Rodrigo R, Prat H, Passalacqua W, et al. Relationship between oxidative stress 
and essential hypertension. Hypertension Research: Official Journal Of The 
Japanese Society Of Hypertension 2007;30(12):1159‐67. 
  26 
49.  Russo C, Olivieri O, Girelli D, et al. Anti‐oxidant status and lipid peroxidation in 
patients with essential hypertension. Journal Of Hypertension 1998;16(9):1267‐
71. 
50.  Kumar KV, Das UN. Are free radicals involved in the pathobiology of human 
essential hypertension? Free Radical Research Communications 1993;19(1):59‐
66. 
51.  Caimi G, Mulè G, Hopps E, et al. Nitric oxide metabolites and oxidative stress in 
mild essential hypertension. Clinical Hemorheology & Microcirculation 
2010;46(4):321‐5. 
52.  Cracowski J‐L, Baguet J‐P, Ormezzano O, et al. Lipid peroxidation is not increased 
in patients with untreated mild‐to‐moderate hypertension. Hypertension 
2003;41(2):286‐8. 
53.  Ward NC, Hodgson JM, Puddey IB, et al. Oxidative stress in human hypertension: 
association with antihypertensive treatment, gender, nutrition, and lifestyle. 
Free Radical Biology & Medicine 2004;36(2):226‐32. 
54.  Wagenknecht LE, Mayer EJ, Rewers M, et al. The insulin resistance 
atherosclerosis study (IRAS) objectives, design, and recruitment results. Annals 
Of Epidemiology 1995;5(6):464‐72. 
55.  Kals J, Kampus P, Kals M, et al. Inflammation and oxidative stress are associated 
differently with endothelial function and arterial stiffness in healthy subjects and 
in patients with atherosclerosis. Scandinavian Journal of Clinical & Laboratory 
Investigation 2008;68(7):594‐601. 
56.  Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care 
2008;31 Suppl 2:S185‐S9. 
57.  Calhoun DA, Oparil S. Racial differences in the pathogenesis of hypertension. The 
American Journal Of The Medical Sciences 1995;310 Suppl 1:S86‐S90. 
58.  Warolin J, Coenen KR, Kantor JL, et al. The relationship of oxidative stress, 
adiposity and metabolic risk factors in healthy Black and White American youth. 
Pediatric Obesity 2014;9(1):43‐52. 
59.  Rodrigo R, Libuy M, Feliú F, et al. Oxidative stress‐related biomarkers in essential 
hypertension and ischemia‐reperfusion myocardial damage. Disease Markers 
2013;35(6):773‐90. 
60.  Il'yasova D, Wang F, Spasojevic I, et al. Urinary F2‐isoprostanes, obesity, and 
weight gain in the IRAS cohort. Obesity (Silver Spring, Md) 2012;20(9):1915‐21. 
61.  Il'yasova D, Wang F, Spasojevic I, et al. Racial differences in urinary F2‐
isoprostane levels and the cross‐sectional association with BMI. Obesity (Silver 
Spring, Md) 2012;20(10):2147‐50.   
